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Abstract
InterFeron Inducible TransMembrane proteins 1–3 (IFITM1, IFITM2 and IFITM3) are a family of proteins capable of inhibiting
the cellular entry of numerous human and animal viruses. IFITM1-3 are unique amongst the currently described viral
restriction factors in their apparent ability to block viral entry. This restrictive property is dependant on the localisation of
the proteins to plasma and endosomal membranes, which constitute the main portals of viral entry into cells. The topology
of the IFITM proteins within cell membranes is an unresolved aspect of their biology. Here we present data from
immunofluorescence microscopy, protease cleavage, biotin-labelling and immuno-electron microscopy assays, showing
that human IFITM1 has a membrane topology in which the N-terminal domain resides in the cytoplasm, and the C-terminal
domain is extracellular. Furthermore, we provide evidence that this topology is conserved for all of the human interferon-
induced IFITM proteins. This model is consistent with that recently proposed for murine IFITM3, but differs from that
proposed for murine IFITM1.
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Introduction
The InterFeron Inducible TransMembrane (IFITM) protein
family of viral restriction factors was defined in 2009 in a screen
for host-modifying proteins of influenza A virus (IAV) infection
[1]. Initially identified over 30 years ago [2], and named 9–27
(IFITM1), 1-8D (IFITM2) and 1-8U (IFITM3) [3], these proteins
received little attention until human IFITM3 depletion was found
to enhance IAV infection in cell culture assays. Conversely, over-
expression of IFITM3, or the closely related IFITM1 and
IFITM2, could inhibit IAV replication [1]. Studies in mice and
humans have suggested that IFITM3, at least, also protects against
IAV infection in vivo [4,5]. However, the IFITM proteins are not
IAV-specific and, in cell culture at least, have broad-spectrum
antiviral activity [6], though in some systems they may enhance
cellular infection of human coronavirus OC43 [7] and human
papillomavirus 16 [8].
Shortly after the identification of IFITM1-3 as antiviral factors,
over-expression of IFITM3 was shown to cause an accumulation
of intact IAV particles in endocytic organelles [9], suggesting that
IFITM3 interfered with viral entry following endocytosis.
Furthermore, this activity was dependent on localisation of
IFITM3 to endosomes [10]. More recent studies suggested that
IFITM over-expression may increase membrane rigidity and
positive curvature, preventing the early events in membrane fusion
[11]. Alternatively, IFITM protein interaction with vesicle
membrane protein associated protein A (VAPA), disrupts choles-
terol homeostasis and may increase membrane rigidity [12].
However, more recent work has questioned the role of cholesterol
[13,14]. Thus, the precise molecular mechanism(s) for IFITM
inhibition of viral entry remains to be established.
From their first descriptions, the IFITM proteins were thought
to be membrane proteins [15]. Indeed, sequence analyses
identified two hydrophobic, putative membrane interacting
domains in each of the proteins. Additional studies demonstrated
palmitoylation of cysteine residues adjacent to the hydrophobic
domains, a post-translational modification indicative of membrane
proteins [16]. However, the membrane topology of the IFITM
proteins has remained ambiguous. Initially, they were suggested to
be dual pass, transmembrane proteins with both N- and C-
terminal domains (NTD and CTD) exposed extracellularly and a
conserved intracellular loop (CIL) (Fig. 1, model 1). This model
was based on the ability of antibodies against unknown IFITM1
external epitopes to aggregate leukaemia cells [15,17], immuno-
precipitation of extracellular radiolabelled IFITM1 [18] and the
accessibility of IFITM3 NTD and CTD epitope tags at the cell
surface by FACS and immunofluorescence assays, respectively [1].
This topology was subsequently challenged by studies demon-
strating that the NTD and CIL domain of IFITM3 are post-
translationally modified by cytoplasmic enzymes [10,19]. More-
over, engineered myristoylation and prenylation sites at the NTD
and CTD of murine IFITM3 can be detected as lipidated with
selective chemical reporters alk-12 and alk-FOH, respectively [19].
These data suggested that both the NTD and CTD of IFITM3 are
intracellular, and that the two hydrophobic sequences, enter, but
do not span, the lipid bilayer [19] (Fig. 1, model 2). Murine
IFITM1 was also proposed to have this topology [20].
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Based on multiple approaches a third model has since been
proposed for mu IFITM3, with the NTD and CIL facing the
cytoplasm and the CTD located in the extracellular space, or
within the lumen of vesicular organelles [21] (Fig. 1, model 3).
While this manuscript was under revision, an additional study
suggested a similar topology for human IFITM3 [22]. However, it
remains unclear whether C-terminal epitope tags influence the
topology, and whether the proposed topology applies to other
human IFITM proteins.
Using immunofluorescence microscopy, protease cleavage
assays, immuno-electron microscopy and biotin-labelling ap-
proaches, our data support the notion that the NTD of human
IFITM1 is located in the cytoplasm, while the CTD is extracellular
(Fig. 1, model 3). We provide evidence that the presence of a HA-
tag at the IFITM1 C-terminus does not induce this topology. We
also show that, although human IFITM2 and IFITM3 reside
predominantly in intracellular membranes, they adopt the same
topology. Together our data are consistent with the recently
proposed model for mu IFITM3 [21], but not with that proposed
for mu IFITM1 [20].
Materials and Methods
Cell lines and constructs
A549 (adenocarcinoma of human lung epithelia) cell lines stably
expressing C-terminally HA-tagged human (hu) IFITM1, IFITM2
or IFITM3, as well as untransfected A549 cells [23], were cultured
in Ham’s F-12-GlutaMAX media (tissue culture reagents were
from Life Technologies, unless indicated otherwise) supplemented
with 10% (v/v) foetal calf serum (FCS) (PAA) and 1% (v/v)
Penicillin/Streptomycin (Pen/Strep, 10,000 unit/ml/10,000 mg/
ml). HEK293T cells were cultured in DMEM-GlutaMAX
supplemented with 10% (v/v) FCS and 1% (v/v) Pen/Strep. All
cell lines were maintained at 37uC and 5% CO2. Untagged
IFITM1 and IFITM1-Vstop (a construct with a stop codon after
Val109) were purchased from GeneArt and cloned into BamH1/
Not1 sites of pcDNA3.1. Constructs were confirmed by sequenc-
ing (Source BioScience).
Antibodies
Rat anti-HA (100 mg/ml, clone 3F10, Roche), mouse anti-HA
(1 mg/ml, clone HA.11, 16B12 Covance), rabbit anti-IFITM1-
NTD (100 mg/ml, Sigma), rabbit anti-IFITM3-NTD (250 mg/ml,
Abgent), rabbit anti-VDAC (1 mg/ml, Abcam), rabbit anti-
calreticulin (Thermo Scientific), mouse anti-tubulin (clone
DM1A, ascites fluid, Sigma), goat anti-rat Alexa-488, goat anti-
rabbit Alexa-488, goat anti-mouse Alexa-594 and goat anti-rabbit
Alexa-647 (all 2 mg/ml, Life Technologies), goat anti-rabbit
IRDye 680 and goat anti-mouse IRDye 800 (1 mg/ml, Li-
COR), and wheat germ agglutinin (WGA) conjugated to Alexa-
647 fluorophore (1 mg/ml, Invitrogen), were used at the dilutions
given below.
Permeabilised immunofluorescence
Cells cultured on coverslips were fixed in 3% (w/v) formalde-
hyde (FA) (TAAB) in phosphate buffered saline (PBS) for
15 minutes (min), quenched with 50 mM NH4Cl and 0.2% (w/
v) bovine serum albumin (BSA, Sigma) in PBS (PBS/BSA) for
15 min and then permeabilised in PBS/BSA and 0.05% (w/v)
saponin (Sigma) (permeabilisation buffer [PB]) for 30 min at room
temperature (RT). Primary antibodies were diluted in PB and
incubated with the coverslips for 1 hour (h). Unbound antibody
was washed off with PB (365 min). Primary antibodies were
detected with appropriate secondary antibodies conjugated to
Alexa-488, Alexa-594 or Alexa-647, again, diluted in PB.
Coverslips were mounted on Mowiol (Sigma) and imaged using
a Leica TSC SPE confocal microscope.
Intact cell immunofluorescence
Cells cultured on coverslips were washed with ice cold PBS/
BSA then incubated with primary antibodies on ice for 1 h in ice
cold PBS/BSA. Cells were washed to remove unbound antibody
and fixed in ice cold 3% FA for 1 h (30 min on ice and 30 min at
RT). Primary antibodies were detected with appropriate second-
ary antibodies in PBS/BSA. Cells were processed and imaged as
described above.
Figure 1. IFITM membrane topology models. In Model 1, the N- and C-terminal domains are extracellular and are connected by two
transmembrane domains (M1 and M2) and the conserved intracellular loop (CIL). In Model 2 the two hydrophobic domains (M1, M2) do not span the
membrane, resulting in NTD, CTD and CIL domain being located in the cytoplasm. In Model 3, the NTD and CIL domain are intracellular, suggesting
M1 does not span the membrane, but the CTD is located on the extracellular side of the membrane and requires that M2 spans the membrane.
doi:10.1371/journal.pone.0104341.g001
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Wheat germ agglutinin staining
WGA-Alexa-647 was bound to cells on ice for 10 min. The cells
were then washed four times with PBS/BSA and labelled using the
intact cell staining procedure described above.
Antibody feeding
Cells cultured on coverslips were incubated in media containing
rat anti-HA for 3 h at 37uC. Unbound antibody was removed, and
the cells then rinsed in PBS, fixed and permeabilised (as above)
before incubation with anti-rat Alexa-488 in PB. Cells were
mounted and imaged as described above.
For all immunofluorescence, the antibodies were used as
follows: rat anti-HA 1:100, rabbit anti-IFITM1-NTD 1:200,
rabbit anti-IFITM3-NTD 1:200, mouse anti-tubulin 1:100, goat
anti-rat Alexa-488, goat anti-rabbit Alexa-488, goat anti-mouse
Alexa-594 and goat anti-rabbit Alexa-647 all 1:500 and WGA-
Alexa-647 1:200. Nuclei were stained with Hoechst-33258
(Sigma).
Image analysis
To calculate the Pearson’s R-value and Mander’s correlation
coefficients, M1 and M2, individual cells were segmented and
analysed using the JACoP plugin on ImageJ software [24]. For M1
and M2 values, a Costes’ automatic threshold was applied (as
described [24]). To calculate the relative areas of yellow, red and
green signals, images were initially split into the red and green
component channels. These two images were then processed with
the ‘AND’ function in ImageJ (producing an image of pixels that
are only both red AND green). This image was subject to a
manual threshold to observe only cellular structures and remove
background noise. The pixel area was then calculated and these
pixels defined as ‘‘yellow.’’ The ‘‘yellow’’ pixels were then super-
imposed on the red and green single channel images, and removed
from each of these (such that a pixel defined as ‘‘yellow’’ cannot be
considered ‘‘red or ‘‘green’’). The same approach of applying a
threshold was then taken on the red channel to calculate the pixel
area, with these being defined as ‘‘red.’’ Again, once calculated,
these ‘‘red’’ pixels were super-imposed on the green channel image
and removed. This allowed a threshold to be applied to the green
channel and the area of the remaining pixels calculated. The
relative area for each colour was calculated for each field of view
and the mean average of all values calculated.
qRT-PCR
The endogenous levels of IFITM1, 2, and 3 mRNA in A549
and HEK293T cells were measured by QuantiTect SYBR green
qRT-PCR (Qiagen) using the primers described in Table 1 and
the following thermocycling conditions: RT step - 50uC for
30 min. PCR steps - 95uC for 15 min, 94uC for 15 s; 35 cycles of
(94uC, 15 s; 60uC, 30 s; 72uC, 30 s) in a reaction volume of 50 ml.
Total RNA was extracted from a known number of cells
(between 2.46105 and 5.96105) and quantitated (RNeasy minikit):
100 ng was used as a template in each qRT-PCR reaction.
Five standards from 107–103 copies were made using plasmids
encoding the transcripts of human IFITM1, 2, and 3, using the
following formula:
x g =½plasmid length| 660| 6:022| 1023 ~ y molecules
Using the standards for each transcript, the quantity of
transcript was determined relative to the standard curve for
100 ng input RNA. The number of copies per cell was estimated
by dividing the total number of cells by the total RNA extracted,
multiplied by 100. This gave the equivalent number of cells that
produced 100 ng of RNA and from this the RNA copy number
per cell was inferred.
Western blotting
Cells were lysed in Triton X-100 lysis buffer (1% [v/v] Triton
X-100, 150 mM NaCl, 50 mM Tris-HCl pH 8.0 and 16
complete protease inhibitor cocktail [Roche]). Protein concentra-
tions were determined using the BCA method (Thermo Scientific)
following the manufacturer’s instructions. Equal amounts of
protein were mixed with reducing 36 Laemmli sample buffer
(LSB), heated at 95uC for 5 min, separated by 15% SDS-PAGE
and semi-dry transferred to a PVDF membrane (Immobilon-FL,
Millipore). Membranes were blocked in TBST (Tris-buffered
saline pH 7.4 [TBS] with 0.05% [v/v] Tween 20) containing 5%
(w/v) dried skimmed milk (Marvel) for 1 h and incubated with
primary antibodies at 4uC overnight. For trypsin cleavage assays,
samples were collected (as described below) and lysed directly in
16 reducing LSB then heated at 95uC for 5 min. Equal volumes
of cell lysates were loaded.
Antibodies used for protein detection were as follows: rabbit
anti-IFITM3-NTD 1:500, rabbit anti-IFITM1-NTD 1:1000,
mouse anti-HA 1:1000 and rabbit anti-VDAC 1:3000. The
primary antibodies were detected using goat anti-rabbit IRDye
680 or goat anti-mouse IRDye 800 secondary antibodies, both at
1:10,000 (in 5% milk-TBST), then imaged and quantified using an
Odyssey system (Li-COR).
Trypsin treatment
IFITM1-HA expressing A549 cells, grown in 6635 mm well
plates, were treated with 100 mg/ml trypsin (Sigma) for 5–30 min
at 37uC. Subsequently, the cells were transferred to microcen-
trifuge tubes on ice, the wells were rinsed with 1 mg/ml soybean
trypsin inhibitor (SBTI) (Sigma) in PBS, and the rinse added to the
microcentrifuge tubes. Untreated control cells, as well as cells
treated with inactivated trypsin (1:1 volume ratio of SBTI to
trypsin), were also collected. All samples were pelleted (5 min,
3000 RCF, 4uC) and washed with SBTI before direct lysis in LSB
and western blotting, as described above.
Flow cytometry
Cells in 35 mm dishes were treated with trypsin for 10 and
30 min or PBS for 30 min (as described above). The cells were
then fixed, quenched (as previously) and washed with PBS/BSA
prior to labelling with rat anti-HA antibody in PBS/BSA for 1 h at
RT. The cells were then washed 36with PBS/BSA and labelled
Table 1. qRT-PCR primers.
Primer name Sequence (59 to 39)
F’Human_IFITM3 ACTGTCCAAACCTTCTTCTCTC
R’Human_IFITM3 AGCACAGCCACCTCGTGCTC
F’Human_IFITM2 ATTGTGCAAACCTTCTCTCCTG
R’Human_IFITM2 ACCCCCAGCATAGCCACTTCCT
F’Human_IFITM1 AGCACCATCCTTCCAAGGTCC
R’Human_IFITM1 TAACAGGATGAATCCAATGGTC
A list of the primers used for qRT-PCR. F9 and R9 stand for forward and reverse,
respectively.
doi:10.1371/journal.pone.0104341.t001
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with goat anti-rat Alexa-647 in PBS/BSA for 45 min. Cells were
washed 36with PBS and subject to flow cytometry (LSR-II; BD
Bioscience). Cells were gated on forward and side scatter and
analysed for fluorescence labelling. The data were processed using
FlowJo vX.0.7 software (Tree Star). Antibodies were diluted as for
immunofluorescence staining.
Biotin labelling and pulldown
HEK293T cells, grown in 10 cm dishes, were transfected with
untagged IFITM1 or IFITM1-Vstop expressing plasmids using
FuGENE6. After 24 h, cells were detached with 5 mM EDTA
and re-plated into 6635 mm well plates. After a further 24 h, cells
were labelled with 1 mg/ml EZ-link Sulfo-NHS-SS-Biotin
(Thermo Scientific) for 45 min at 37uC. The biotin label was
washed off with TBS and the cells lysed with 100 ml Triton X-100
lysis buffer (as previously). The whole cell lysate (70 ml) was added
to a 25 ml NeutrAvidin agarose bead pellet (Thermo Scientific)
and incubated for 3 h at 4uC on a rotor. Beads were then pelleted
and the unbound material collected. The bead pellet was then
washed with Triton X-100 lysis buffer, TBS and a TE buffer
(10 mM Tris, 5 mM EDTA), prior to elution of proteins in 70 ml
of 16 reducing LSB and heating at 95uC for 10 min. Eluate was
collected and the elution procedure repeated. Equivalent volumes
of whole cell lysate, unbound material and eluate from the
NeutrAvidin beads were separated by 15% SDS-PAGE and
western blotted as previously. Calreticulin was used as a loading
control and detected with an anti-calreticulin antibody diluted
1:5000 in 1% BSA-TBST.
Electron microscopy
Cells were fixed with 4% (w/v) FA in 0.1 M phosphate buffer
pH7.4, infused with 2.3 M sucrose, supported in 12% (w/v)
gelatin and frozen in liquid nitrogen. Ultrathin (70 nm) cryosec-
tions were cut at 2120uC and picked up in 1:1 2% sucrose:-
methylcellulose. Sections were labelled with primary antibody
(mouse anti-HA 1:400), followed by rabbit anti-mouse intermedi-
ate antibody (DAKO) and protein A gold, as described [25,26].
Images were obtained using a Tecnai T12 transmission electron
microscope (FEI) and captured using a Morada CCD camera
(Olympus-SIS).
Results
The human IFITM1 C-terminal domain resides
extracellularly
To investigate the cellular distributions of human (hu) IFITM1,
2 and 3 we used C-terminally HA-tagged proteins, stably
expressed in A549 cells, and immunofluorescence microscopy.
When cells were permeabilised and labelled with anti-HA
antibodies, all three IFITM proteins were detected, and each
had a different cellular distribution. IFITM1-HA was seen
primarily at the plasma membrane (Fig. 2B). By contrast,
IFITM2-HA and IFITM3-HA were seen mostly in intracellular
compartments with distinct distributions. IFITM2-HA localised in
a tight cluster of punctae close to the nucleus, while IFITM3-HA
had a more dispersed, punctate distribution (Fig. 2C and D).
Cells were also stained in the absence of detergent, thus
maintaining the integrity of the plasma membrane. For IFITM1,
anti-HA labelling was very similar on intact and detergent-
permeabilised cells (compare Fig. 2F and Fig. 2B). As a control for
the integrity of the plasma membrane, cells were co-stained with
an anti-tubulin antibody (Fig. S1). Detection of IFITM1-HA on
non-permeabilised cells further demonstrated that the protein is
located primarily at the cell surface in stable transfected A549
cells. Furthermore, the C-terminal HA-tag is accessible on intact
cells and therefore located on the extracellular surface of the
plasma membrane. Co-staining cells with fluorescent wheat germ
agglutinin further confirmed this plasma membrane localisation
(Fig. S2).
No anti-HA labelling was seen on intact IFITM2-HA express-
ing cells, in keeping with the notion that this protein is located on
intracellular membranes (Fig. 2G). A similar result was seen for
IFITM3-HA, although a low number of cells (,1%) did show
some surface labelling with anti-HA antibodies (Fig. 2H and Fig.
S3). This suggested that although the majority of IFITM3-HA is
located on intracellular membranes (Fig. 2D), in some cells
IFITM3-HA is either mis-sorted and/or is expressed at the cell
surface where the C-terminal HA epitope is accessible.
IFITM N-terminal domains reside intracellularly
The observation that the HA-tag of IFITM1 is accessible at the
surface of intact cells prompted us to investigate the topology of
the protein. We used two commercially available antibodies
against the hu IFITM1 and IFITM3 NTDs. The IFITM1 NTD
antibody (anti-IFITM1-NTD) was raised against a peptide
encoding the first 35 amino acids of hu IFITM1. This domain
has 69% and 75% amino acid identity with hu IFITM2 and
IFITM3, respectively. The IFITM3 NTD antibody (anti-IFITM3-
NTD) was raised against a peptide with a sequence corresponding
to the first 30 amino acids of hu IFITM3. Hu IFITM1 has an N-
terminal 21 amino acid truncation compared to IFITM3, so
contains only 9 amino acids overlapping with this domain.
However, there is 90% amino acid identity between the first 30
amino acids of hu IFITM3 and IFITM2.
To determine the specificity of the NTD antibodies, both were
tested on samples from the HA-tagged IFITM1-3 expressing A549
cells by western blot analysis. Anti-IFITM1-NTD detected
IFITM1-HA and IFITM3-HA, but not IFITM2-HA (Fig. 3A).
Anti-IFITM3-NTD detected both IFITM3-HA and IFITM2-HA,
but not IFITM1-HA (Fig. 3B). No IFITM protein was detected in
control A549 cells with either antibody by western blot. Multiple
bands in the range of 12–17 kDa were seen with the NTD
antibodies, but not the anti-HA, indicating possible post-transla-
tional modification of the proteins (see below).
When intact IFITM1, 2 or 3 cells were labelled with anti-
IFITM1-NTD antibody, no staining was seen, suggesting intra-
cellular NTDs (Fig. 4J, K and L). Following detergent treatment,
all three IFITM expressing lines were labelled (Fig. 4B, C and D),
though a weaker signal was seen for IFITM2, as expected from the
western blot (Fig. 3A). By immunofluorescence, the anti-IFITM3-
NTD antibody gave a low signal in the untransfected A549 control
and IFITM1-HA cells (Fig. 4E and D), consistent with the low
level of endogenous IFITM2 expression detected by qRT-PCR
(Fig. S4). However, the antibody clearly detected IFITM2-HA and
IFITM3-HA (Fig. 4G and H). The observed cellular distributions,
using the anti-NTD antibodies, agree with those seen using anti-
HA antibodies (Fig. 2), and the inaccessibility of the IFITM1-
NTD to labelling on intact cells indicates the domain is on the
cytoplasmic side of the plasma membrane.
The IFITM1 C-terminal domain is accessible to
extracellular proteases
Immunofluorescence microscopy (Fig. 2 and 4) suggested that
the IFITM1 C-terminal HA-tag resides on the extracellular face of
the plasma membrane, while the NTD is cytoplasmic. To further
investigate this topology, we used protease cleavage assays. Since
IFITM1-HA is primarily localised to the plasma membrane we
hypothesised that the CTD, and HA-tag, might be accessible to
Human IFITM1 Membrane Topology
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digestion by extracellular proteases. Following analysis of the
human IFITM1 CTD sequence with the ExPASy ‘PeptideCutter’
tool (http://web.expasy.org/peptide_cutter/) we chose to use
trypsin, which was predicted to cleave at two positions close to the
C-terminus of hu IFITM1 and thus expected to release the HA-tag
(Fig. 5A).
IFITM1-HA cells were incubated with trypsin for up to 30 min
at 37uC. The trypsin was then inactivated by addition of excess
soybean trypsin inhibitor (SBTI) and the cells analysed by western
blot using antibodies against both the C-terminal HA-tag and the
NTD. Analysis of samples from untreated cells with anti-IFITM1-
NTD indicated two IFITM1 bands (Fig. 5Bi), as previously seen
(Fig. 3A). In samples from trypsin-treated cells the higher
molecular weight band was rapidly lost, with a concomitant
increase in the intensity of the lower band (Fig. 5Bi). This
suggested that the higher molecular weight band is IFITM1-HA
(confirmed in an anti-HA and anti-IFITM1-NTD overlay analysis
[Fig. 5Biii]), and that the lower band is a cleavage product that has
lost the HA-tag. We noted that about 8% (relative to untreated
samples) of the HA-tagged protein was not digested by trypsin,
even after long periods, suggesting that a small pool of IFITM1-
HA protein was inaccessible to the protease (see below).
We also analysed trypsin cleavage of the HA epitope by flow
cytometry. Cells were treated with trypsin for 10 or 30 min and
the trypsin inactivated with SBTI. Cells were then fixed and
labelled with an anti-HA antibody and detected with an Alexa-647
conjugated secondary antibody. Untreated IFITM1-HA cells
showed a high level of staining that was lost upon treatment with
trypsin, as determined by a shift in the peak fluorescence intensity
and decrease in mean fluorescence intensity (Fig. S5).
Topology of untagged IFITM1
To exclude the possibility that C-terminal tagging influences the
topology of IFITM1, we made use of a lysine residue (K122)
present in the CTD that, if the observed topology is correct, will be
accessible to labelling with NHS-biotin (Fig. 6A). To investigate
this hypothesis, HEK293T cells were transfected with an untagged
IFITM1 expression plasmid and incubated with cell impermeable
Sulfo-NHS-SS-Biotin for 45 min at 37uC. While HEK293T cells
appear to have a low level of IFITM1 mRNA (Fig. S4), no protein
was detected by western blot of mock transfected cells (Fig. 6Biii).
Following biotin labelling of untagged IFITM1, cell lysates were
precipitated using NeutrAvidin beads and analysed by western
blot. IFITM1 labelled by biotin, and precipitated, is readily
detected compared to unlabelled samples (Fig. 6B). The detection
of IFITM1 in the biotin labelled, but unbound, fraction suggested
that either the precipitation is not efficient, or only a proportion of
IFITM1 has a CTD that is accessible to cell surface labelling.
To control for the specificity of labelling, a plasmid encoding an
IFITM1 protein with a stop codon after the V109 codon (referred
to as IFITM1-Vstop) that removes K122 (Fig. 6A), was transfected
into HEK293T cells (Fig. 6C). After cells expressing this protein
were incubated with Sulfo-NHS-SS-Biotin, none of the IFITM1-
Vstop was absorbed to the beads (Fig. 6D).
Figure 2. Cellular distribution of the human IFITM proteins. C-terminal domain HA-tagged IFITM1, IFITM2, IFITM3 and control A549 cell lines
were stained intact, or following permeabilisation, with an anti-HA antibody and a secondary anti-rat Alexa-488 antibody. A) Permeabilised A549 cells
show no specific staining. B-D) IFITM1-HA, IFITM2-HA and IFITM3-HA have distinct cellular distributions in permeabilised cells. E) Intact A549 cells (no
detergent treatment) show no specific staining. F) Intact IFITM1-HA cells show positive cell surface HA staining. G) Intact IFITM2-HA cells show no
detectable HA staining. H) Although the majority of intact IFITM3-HA cells show no anti-HA labelling, a minority (,1%) show low-level positive
staining. Nuclei were labelled with Hoechst. All images are maximum projections of 0.25 mm optical sections taken through the depth of the cells
using a confocal microscope. All images were taken using the same microscope settings and the levels adjusted uniformly. Scale bar represents
15 mm.
doi:10.1371/journal.pone.0104341.g002
Figure 3. Analysis of IFITM NTD antibodies. Two commercially
available antibodies targeting either the IFITM1-NTD or the IFITM3-NTD
were screened by western blot to assess specificity using HA-tagged
IFITM1-3 (M1, M2 and M3) cell lines along with control A549 cells.
Proteins were also identified using the HA epitope. Blots were imaged
on a Li-COR Odyssey system that uses far-red fluorophore conjugated
secondary antibodies. In the overlay image, red represents anti-IFITM-
NTD labelling and green represents anti-HA labelling. A) Anti-IFITM1-
NTD detects IFITM1 and shows cross-reactivity with IFITM3. B) Anti-
IFITM3-NTD detects IFITM3 and has cross-reactivity with IFITM2. VDAC
was used as a loading control.
doi:10.1371/journal.pone.0104341.g003
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Figure 4. Analysis of the cellular distribution of the human IFITM proteins using anti-N-terminal domain antibodies.
Immunofluorescence of A549 cells expressing HA-tagged IFITM1, IFITM2 and IFITM3 (or control A549 cells) using anti-IFITM1-NTD and anti-IFITM3
NTD antibodies. A) Permeabilised A549 cells show no specific staining. B-D) IFITM1-HA, IFITM2-HA and IFITM3-HA show distinct distributions in
permeabilised cells. E and F) Anti-IFITM3-NTD detects low levels of endogenous protein in control A549 and IFITM1-HA cell lines. G and H) Anti-
IFITM3-NTD detects IFITM2-HA and IFITM3-HA in permeabilised cells. I-L) No specific staining was seen on intact cells labelled with anti-IFITM1-NTD
antibody. Nuclei were labelled with Hoechst. All images are maximum projections of 0.25 mm optical sections taken through the depth of the cells on
a confocal microscope. All images were taken using the same microscope settings and the levels adjusted uniformly. Scale bar represents 15 mm.
doi:10.1371/journal.pone.0104341.g004
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The IFITM1 CTD HA-tag resides on the outer leaflet of the
plasma membrane
To analyse hu IFITM1 in more detail, cryo-sections of IFITM1-
HA cells were immuno-gold labelled for the HA-tag and examined
by electron microscopy. As expected, labelling was seen predom-
inantly at the plasma membrane (Fig. 7A and B). Close
examination indicated that the majority of gold particles resided
on the extracellular face of the plasma membrane, consistent with
the notion that the hu IFITM1 CTD is located extracellularly.
Labelling was also seen in the Golgi apparatus and in multi-
vesicular bodies (Fig. 7C and D). These intracellular pools
presumably indicate IFITM1 trafficking in the biosynthetic and
endocytic pathways. This material would be inaccessible to
extracellular proteases and labelling reagents, explaining the
failure to completely digest IFITM1-HA with trypsin (Fig. 5B)
and to fully label IFITM1 with biotin (Fig. 6B).
Conservation of the observed hu IFITM1 topology in hu
IFITM2 and IFITM3
Our results indicate that hu IFITM1 is located predominantly
in the plasma membrane, making it highly amenable to the
topological analysis described above. Conversely, we show that hu
IFITM2-HA and IFITM3-HA are primarily intracellular and less
accessible to these investigative methods. Alternative approaches
were therefore adopted to determine the location of the HA-
tagged CTD of hu IFITM2 or IFITM3.
An antibody-feeding approach was used in which live cells were
cultured in medium containing anti-HA antibody for 3 h, prior to
washing, fixation and visualisation by immunofluorescence
microscopy. As expected, control untransfected A549 cells,
incubated with anti-HA antibodies, and IFITM3-HA cells that
were not incubated with anti-HA antibodies, showed no labelling
(Fig. 8A and C). IFITM1-HA expressing cells acted as a positive
control and showed strong cell surface labelling (Fig. 8B). By
contrast, most IFITM2-HA and IFITM3-HA cells showed little, if
any, labelling. However, approximately 25% of IFITM3-HA cells
and 10% of IFITM2-HA cells (calculated from 30 random fields of
view at 40X magnification) showed intracellular, punctate
labelling (Fig. 8D and E). Since the cells were labelled prior to
fixation, this intracellular labelling suggested that, in some cells,
the IFITM2-HA and IFITM3-HA proteins are trafficked to the
cell surface where an externally exposed HA epitope could bind
antibody, prior to internalisation into intracellular organelles. The
lack of labelling in the majority of cells, which express the IFITM
proteins, indicates the labelling is not due to non-specific fluid
phase uptake of antibody. Together, we conclude that, in a
Figure 5. Trypsin cleavage of HA-tagged IFITM1. A) Predicted trypsin cleavage sites in hu IFITM1 CTD (Model 3, Fig. 1). B) IFITM1-HA cells were
treated with exogenous trypsin for 5 to 30 mins at 37uC. The trypsin was inactivated with soybean trypsin inhibitor, the cells were lysed and the
cellular proteins separated by SDS-PAGE. After transfer, proteins were identified with anti-IFITM1-NTD (i) and anti-HA (ii) antibodies. VDAC was used
as a loading control (iii). Control samples were untreated (UN), or treated with SBTI-inactivated trypsin (IN). In the overlay image, red represents anti-
IFITM1-NTD labelling and green represents anti-HA labelling (iv).
doi:10.1371/journal.pone.0104341.g005
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fraction of A549 cells, the CTDs of both IFITM2-HA and
IFITM3-HA proteins are, at least transiently, exposed on the cell
surface.
Previous results have suggested that IFITM2 and 3 are localised
to endosomes (Fig. 2, 4 and [6]). The exposure of CTD HA-tags in
the lumen of these organelles may result in their cleavage by
endosomal/lysosomal proteases. This hypothesis is supported by
western blots that showed low levels of HA-labelling for IFITM2
and 3 (Fig. 3). Moreover, when detected with anti-IFITM3-NTD,
IFITM2-HA appears to have 3 bands in the range of 12–17 kDa,
Figure 6. Biotin labelling and pulldown of untagged IFITM1. Untagged, wild type IFITM1 or IFITM1-Vstop expression plasmids were
transfected into HEK293T cells. After two days the cells were labelled with cell impermeable Sulfo-NHS-SS-Biotin prior to incubation with NeutrAvidin
agarose beads. A) Diagram to show the exposed CTD of IFITM1, with the targeted K122, or IFITM1-Vstop. B) Western blots probed with anti-IFITM1-
NTD; WCL – whole cell lysates, UB – material that remained unbound by NeutrAvidin, PD1 and PD2 – two rounds of elution of protein from the
NeutrAvidin beads. Gel i shows samples from cells labelled with biotin, gel ii shows unlabelled samples and gel iii shows samples from mock
transfected HEK293T cells that were treated with Sulfo-NHS-SS-Biotin. NB. The elution step detached some NeutrAvidin monomers from the beads.
These run at approximately 14 KDa and are seen as background bands in the western blots (labelled ‘NeutrAvidin’). Calreticulin was used as a loading
control and negative control for pulldown specificity. C) Western blot comparing the wild type IFITM1 (M1) with IFITM1-Vstop (Vstop), along with
mock transfected HEK293T cells. D) Western blots probed with anti-IFITM1-NTD for whole cell lysates (i) material that remained unbound to
NeutrAvidin (ii) and protein eluted from the NeutrAvidin beads (iii). As previously, NeutrAvidin monomers were eluted, and have the same molecular
weight at IFITM1-Vstop. This can be clearly seen in the pulldown blot due to the presence of a band in the unlabelled lane.
doi:10.1371/journal.pone.0104341.g006
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with the majority of the protein being of the lowest molecular
weight, consistent with this protein having lost its HA-tag. A
similar low molecular weight form was also seen for IFITM3-HA
(Fig. 3).
IFITM expressing A549 cells were co-stained with antibodies
against the NTD and the HA-tag. As IFITM proteins are
relatively short (less than 133 amino acids) co-staining for the NTD
and CTD should give apparent co-localisation. IFITM1-HA
expressing cells showed a high degree of overlap between the anti-
IFITM1-NTD and anti-HA antibodies (Fig. S6A). The overlap
was seen across multiple images as demonstrated by Mander’s
correlation coefficients M1 and M2. Furthermore, analysis of the
areas of different pixel colours demonstrated that around 70%
(61.8%) of pixels were detectable as yellow (Table S1).
By contrast, on IFITM3-HA expressing cells, a lower level of co-
localisation was seen with both NTD antibodies (Fig. 9B and Fig.
S6C). Importantly, clear red punctae were visible, suggesting that
in some organelles IFITM3 contains intact NTDs but lacks the
CTD HA-tag. This conclusion is supported by the quantification
of multiple images that demonstrate a lower Mander’s M1 and
M2, compared to IFITM1-HA, and show an excess of red pixels
(55% [61.4%]) for IFITM3-HA expressing cells (Table 2, 3 and
Table S1).
The anti-IFITM1-NTD antibody does not detect IFITM2-HA
as well as IFITM1-HA and IFITM3-HA (Fig. 3); we therefore
used the anti-IFITM3-NTD antibody for a similar investigation of
IFITM2-HA (Fig. 9A). When multiple images were quantified, the
results for IFITM2-HA and IFITM3-HA expressing cells were
largely equivalent, with 49% (61.1%) of pixels being red for
IFITM2-HA cells, compared to 46% (60.9%) for IFITM3-HA
cells (Table 2 and 3). The observed excess of red pixels for both
IFITM2-HA and IFITM3-HA indicates loss of the HA-tag,
consistent with the western blots (Fig. 3). Overall, the data suggest
a topology in which the HA-tagged CTDs of IFITM2 and
IFITM3 are exposed to the endosomal/lysosomal system.
Discussion
The membrane topology of the interferon-induced IFITM
proteins has been controversial. Initially it was suggested that both
the NTD and CTD are located on the extracellular face of
membranes and are connected by two transmembrane domains
and the CIL domain (Fig. 1, model 1) [1,15,17,18]. However
subsequent studies, demonstrating post-translational modification
of both the hu IFITM3 NTD and CIL domain by cytosolic
enzymes, led to the proposal of a model that placed the NTD, CIL
and CTD all within the cytoplasm (Fig. 1 model 2) [10,19]. The
same topology was also suggested for mu IFITM1 [20].
Here we present evidence that hu IFITM1, which localises
primarily to the plasma membrane, has a topology with the NTD
located in the cytoplasm and the CTD in the extracellular space
Figure 7. Immuno-gold labelling of A549 IFITM1-HA cell cryo-sections. Cryo-sections of the IFITM1-HA cells were labelled with anti-HA
antibodies and Protein A gold. A) Plasma membrane labelling. B and C) Plasma membrane and multi-vesicular body labelling. D) Plasma membrane
and Golgi apparatus labelling. Scale bars represent 200 nm.
doi:10.1371/journal.pone.0104341.g007
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(Fig. 1, model 3). Immunofluorescence microscopy showed that on
non-permeabilised cells the NTD is not accessible to antibody
labelling, whereas the CTD (through an HA-tag) is accessible. In
agreement, the majority of tagged IFITM1 was accessible to
cleavage by exogenous trypsin.
Our results also suggested that the HA-tag itself did not induce
the extracellular CTD topology since untagged IFITM1 could be
biotinylated at K122 using a cell impermeable biotin-labelling
reagent. However, while a large proportion of untagged IFITM1
could be biotin labelled and absorbed to NeutrAvidin beads, some
protein remained in the supernatant. We propose that the
unlabelled protein is that which resides in intracellular compart-
ments such as the Golgi and multi-vesicular bodies, as seen by EM
(Fig. 7), and that there could also be accessibility issues at the
plasma membrane due to the short length of the CTD.
Although not accessible on intact cells, the NTD of IFITM1 was
accessible to labelling with antibodies following detergent treat-
ment of cells and showed a very similar cellular distribution to that
seen with CTD anti-HA labelling. The NTD contains two
potential trypsin cleavage sites, but we saw no evidence of these
sites being accessible to exogenous trypsin. Thus our results are
consistent with a model recently proposed for murine and human
IFITM3 indicating a cytoplasmic NTD and CIL domain,
connected by an intramembrane hydrophobic domain (M1) that
does not fully span the membrane, and a second transmembrane
domain (M2) linking the CIL domain to an extracellular CTD
[21,22]. Our results with antibody labelling experiments indicate
that hu IFITM2 and 3 are likely to have the same topology,
suggesting this may be a common feature of human interferon-
induced IFITM proteins, and mu IFITM3. However, this model is
not consistent with published data on mu IFITM1 [20], in which
palmitoylation of a CTD cysteine (mu IFITM1 C103) suggested a
cytoplasmic location. This cysteine is not conserved in hu IFITM1,
perhaps indicating why there is an apparent difference between hu
and mu IFITM1 [20]. Whether palmitoylation of mu IFITM1 or
other non-human IFITM proteins influence protein topology and/
or its cellular distribution, as well as any possible effects on
functional activities, remains to be examined.
The model for mu IFITM3 [21] and proposed here for hu
IFITMs has important implications. Many studies of the IFITM
proteins have used tagged constructs. If these tags are at the C-
terminus they will reside in extracellular and lumenal spaces where
they may be exposed to proteolytic conditions. Indeed, our results
suggest that, even under normal culture conditions, IFITM-HA
Figure 8. Antibody feeding of IFITM expressing cells. Live A549-IFITM-HA cells were incubated with 5 mg/ml anti-HA at 37uC to allow
endocytosis of bound antibody molecules. Subsequently, the cells were washed, fixed, permeabilised and incubated with an anti-rat Alexa-488
conjugate. A) Control A549 cells show no specific staining. B) In IFITM1-HA cells the majority of labelling is at the plasma membrane. C) IFITM3-HA
cells that were not incubated with anti-HA antibody show no labelling. For IFITM2-HA and IFITM3-HA expressing cells (D and E) the majority of cells
are not labelled, however in both cases a minority of cells do show punctate labelling indicative of IFITM-mediated internalisation of anti-HA
antibodies. In D and E, the boxed region has been enlarged. All images were taken using the same microscope settings and adjusted uniformly. Scale
bars represent 15 mm.
doi:10.1371/journal.pone.0104341.g008
Human IFITM1 Membrane Topology
PLOS ONE | www.plosone.org 11 August 2014 | Volume 9 | Issue 8 | e104341
expressing cells have cleavage products resulting from the loss of
the HA-tag or residues from the CTD itself. Western blots of A549
cells stably expressing IFITM1 show two bands when using the
anti-IFITM1-NTD antibody. The higher molecular weight band
is the HA-tagged form of the protein, while the lower weight band
is a cleaved form of the protein that has lost the HA-tag, and
possibly other residues from the CTD. Since this band is seen in
cells that were not treated with trypsin, we suggest that this C-
terminal cleavage may occur in the endosomal system. This
conclusion is supported by the observation that in A549 cells
expressing HA-tagged IFITM2 or 3, intracellular organelles can
be seen that contain IFITM2 or 3 with intact NTD epitopes but
lacking the CTD HA-tag (Fig. 9).
The potential for loss of the CTD or C-terminal tags will affect
the interpretation of cell localisation studies that rely on CTD
epitopes. IFITM3 has been localised to endosomal compartments
that co-label with markers for early and late endosomes
(transferrin, CD63, Rab proteins, LAMP1, LAMP2 and Lyso-
Tracker Red (as a marker for acidic compartments)
[4,9,12,27,28]), but IFITM2 has proved harder to localise.
Reliance on CTD epitope tags to determine the cellular
distribution of the protein may not reveal the full cellular content
of protein, and functionally important pools may be overlooked.
The relevance of the proposed topology to IFITM protein
function is unclear at this stage. To date, published work has found
that functionally important residues are located within the NTD
[27] and the conserved CD225 domain [19,29], comprising the
membrane interacting domains and the CIL loop, as well as the
second membrane domain that is proposed to interact with VAPA
[12]. Our data suggest the first membrane domain enters into, but
does not span, the lipid bilayers, perhaps allowing the protein to
induce membrane curvature. It could be further speculated that an
Figure 9. Co-staining with N- and C-terminal antibodies. Permeabilised IFITM2-HA (A) and IFITM3-HA (B) expressing cells were stained with
antibodies against the C-terminal HA-tag (green [Alexa-488]) and the NTD, using the anti-IFITM3-NTD antibody (red [Alexa-647]). Images are single
optical sections (0.25 mm thick) through the cells. Scale bars represent 15 mm. See also Table 2 and 3 for image analysis.
doi:10.1371/journal.pone.0104341.g009
Table 2. Image analysis of anti-IFITM3-NTD antibody and anti-HA antibody co-labelling.
Cell line Number of cells imaged Pearson’s R value Mander’s M1 Mander’s M2
IFITM2 57 0.73 (60.13) 0.85 (60.16) 0.86 (60.14)
IFITM3 49 0.72 (60.04) 0.75 (60.21) 0.77 (60.17)
Co-localisation analysis of multiple images, for each cell line, from two independent experiments. Pearson’s R-value represents the correlation in intensity between the
red (anti-IFITM3-NTD) and green (HA) channels. Mander’s correlation coefficients, M1 and M2, represent the overlap of red, in pixels that are green, and the overlap of
green, in pixels that are red, respectively. Error given is of the standard deviation.
doi:10.1371/journal.pone.0104341.t002
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extracellular CTD may allow IFITM proteins to interact with key
membrane components that are inaccessible on the cytoplasmic
face of the membrane.
In conclusion, our data, together with those recently published
for mu and hu IFITM3, provide a compelling case for hu IFITM
proteins having an intracellular NTD and CIL domain, and an
extracellular CTD. Whether all vertebrate IFITM proteins
conform to the same organisation and, if not, the functional
implications of other topologies, remain to be established.
Supporting Information
Figure S1 Tubulin co-staining on intact and permeabi-
lised IFITM cell lines. C-terminal domain HA-tagged
IFITM1-3 and A549 cell lines were co-stained intact, or following
permeabilisation, with an anti-HA antibody and an anti-tubulin
antibody. These antibodies were detected with Alexa-488 (green)
and Alexa-594 (red), respectively. A) Permeabilised IFITM-HA
cells show positive labelling for all IFITM proteins and tubulin. B)
Intact IFITM-HA cells show no labelling for tubulin, indicating
that the plasma membrane has remained intact and the antibody
does not have access to the cytoplasm. As previously, IFITM1-HA
can be labelled on intact cells, IFITM2-HA has no labelling and
only a minority of IFITM3-HA expressing cells shows plasma
membrane labelling. Nuclei were labelled with Hoechst. All
images are maximum projections of 0.25 mm optical sections taken
through the depth of the cells on a confocal microscope. All images
were taken using the same microscope settings and the levels
adjusted uniformly. Scale bars represent 15 mm.
(TIF)
Figure S2 Wheat germ agglutinin co-staining on intact
IFITM cell lines. IFITM-HA cell lines co-labelled with anti-HA
antibody, detected with Alexa-488 (green channel) and WGA-
Alexa-647 (red channel). Images are of a single optical section
(0.25 mm thick) through the middle surface of the cells. Scale bars
represent 15 mm.
(TIF)
Figure S3 Immunofluorescence of intact IFITM3 cells.
Intact IFITM3-HA cells stained with anti-HA antibody. A
minority (,1%) of the cells show some plasma membrane
labelling, although the vast majority do not. Labelling of
permeabilised cells showed that all cells express IFITM3-HA
(Fig. 2D) Scale bar represents 15 mm. The boxed region is
enlarged in the right hand panel.
(TIF)
Figure S4 qRT-PCR of A549 and HEK293T cells. qRT-
PCR of A549 and HEK293T cells to determine the expression
levels of any endogenous IFITM proteins. Each bar is labelled
with the mean number of RNA copies per cell with error bars
representing the standard deviation from n= 3 amplifications.
(TIF)
Figure S5 Trypsin cleavage and flow cytometry analysis
of IFITM1-HA. IFITM1-HA cells were treated with exogenous
trypsin for 10 and 30 mins at 37uC. The trypsin was inactivated
with soybean trypsin inhibitor, and cells fixed then labelled with
anti-HA antibody. The HA labelling was detected with anti-rat
Alexa-647 and the cells analysed by flow cytometry. A) Histograms
representing the fluorescence intensity of HA labelling. The black
line represents control A549 cells expressing no HA constructs.
The green line represents untreated IFITM1-HA cells. The blue
and red lines represent 10 and 30 mins of trypsin treatment,
respectively. B) Mean fluorescence intensity of HA labelling. Data
represent mean averages from n= 2 cleavages and error bars equal
standard deviation.
(TIF)
Figure S6 Co-staining with anti-IFITM1-NTD and anti-
HA antibodies. Permeabilised IFITM1-HA (A), IFITM2-HA
(B) and IFITM3-HA (C) expressing cells were stained with
antibodies against the C-terminal HA-tag (green [Alexa-448])
and the NTD, using the anti-IFITM1-NTD antibody (red [Alexa-
647]). Images are of single optical sections (0.25 mm thick) through
the middle the cell. Scale bars represent 15 mm.
(TIF)
Table S1 Image analysis of anti-IFITM1-NTD antibody
and anti-HA antibody co-labelling. Co-localisation analysis
of multiple images, for each cell line, from three independent
experiments. Pearson’s R-value represents the correlation in
intensity between the red (anti-IFITM1-NTD) and green (HA)
channels. Mander’s correlation coefficients, M1 and M2, represent
the overlap of red, in pixels that are green, and the overlap of
green, in pixels that are red, respectively. Relative areas of each
colour were calculated as described in materials and methods.
Error given is of the standard deviation.
(DOCX)
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Table 3. Image analysis of anti-IFITM3-NTD antibody and anti-HA antibody co-labelling.
Cell line Fields of view Yellow relative area Red relative area Green relative area
IFITM2 13 0.26 (60.07) 0.49 (60.11) 0.25 (60.09)
IFITM3 14 0.27 (60.04) 0.46 (60.09) 0.27 (60.09)
Relative areas of each colour were calculated as described in materials and methods. Red represents anti-IFITM3-NTD labelling, green represents anti-HA labelling and
yellow represents overlap of the two stains. Error given is of the standard deviation.
doi:10.1371/journal.pone.0104341.t003
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